Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE , ADVANCE and FORTIFY clinical trials - Université de Lorraine Access content directly
Journal Articles Alimentary Pharmacology & Therapeutics (Suppl) Year : 2023

Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE , ADVANCE and FORTIFY clinical trials

Dates and versions

hal-04168408 , version 1 (21-07-2023)

Identifiers

Cite

Laurent Peyrin‐biroulet, Subrata Ghosh, Scott Lee, Wan-Ju Lee, Jenny Griffith, et al.. Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE , ADVANCE and FORTIFY clinical trials. Alimentary Pharmacology & Therapeutics (Suppl), 2023, 57 (5), pp.496-508. ⟨10.1111/apt.17242⟩. ⟨hal-04168408⟩
11 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More